Abstract
The Converge IDE Trial demonstrated improved patient outcomes in a challenging persistent and long-standing persistent atrial fibrillation population using a heart team hybrid approach with epicardial and endocardial staged ablations. Surgeons encounter unique circumstances with the surgical epicardial stage of the Convergent procedure which includes unfamiliarity with left atrial posterior anatomy, endoscopic/thoracoscopic visualization, minimally invasive left atrial appendage management, and expanded indications for the procedure. Overcoming these unique challenges is key to the adoption of the Convergent procedure as a critical off-pump approach that should be part of the surgical armamentarium in the treatment of atrial fibrillation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
